← Clearmind Medicine Inc. Common Shares overview

Clearmind Medicine Inc. Common Shares vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Clearmind Medicine Inc. Common Shares (CMND)

Q3 2026
▲3

Clearmind's alcohol drug trial hits safety goal, but EV charging pivot raises questions

  • CMND-100 clears key safety hurdle in alcohol use disorder trial Clearmind's lead drug CMND-100 met its main safety goal in Part A of a Phase 1/2 trial: all 24 healthy volunteers finished dosing, with no serious side effects across four dose levels. This is the biggest de-risking event so far and supports moving into patients with alcohol use disorder.

    This is the single most important new event for CMND's core drug program and directly drives the stock's value.

  • Early trial buzz and better nasal formulation support the drug story Doctors at Yale and Johns Hopkins gave a positive early read on CMND-100, noting it is non-hallucinogenic, which could mean simpler treatment without hospitalization. Separately, lab data showed Clearmind's nasal MEAI formula sticks to tissue better, a small but useful development step.

    These two updates build confidence in the drug's differentiation and delivery before the formal safety result.

  • Clearmind pivots into EV wireless charging with 51% acquisition Clearmind signed a definitive deal to buy 51% of Charging Robotics, an EV wireless charging firm, for $2.5 million plus a $1.5 million loan, closing around September 7. It is a surprising move away from its psychedelic-medicine focus and could distract or dilute, though it may add a new revenue path.

    This is a major strategic shift that changes what Clearmind is as a company and raises real questions for investors.

  • Big pharma money flowing into psychedelics lifts the whole sector Eli Lilly agreed to pay up to $3.8 billion for AtaiBeckley, a major vote of confidence in psychedelic medicine. Large cannabis deals also made headlines. A rising tide of sector interest can pull small stocks like Clearmind higher, though it does not change Clearmind's own results.

    Sector-wide deal activity is a real force behind small psychedelic stocks, even if it is not company-specific.

August 2026
▲3

Clearmind's alcohol drug trial hits safety goal, but EV charging pivot raises questions

  • CMND-100 clears key safety hurdle in alcohol use disorder trial Clearmind's lead drug CMND-100 met its main safety goal in Part A of a Phase 1/2 trial: all 24 healthy volunteers finished dosing, with no serious side effects across four dose levels. This is the biggest de-risking event so far and supports moving into patients with alcohol use disorder.

    This is the single most important new event for CMND's core drug program and directly drives the stock's value.

  • Early trial buzz and better nasal formulation support the drug story Doctors at Yale and Johns Hopkins gave a positive early read on CMND-100, noting it is non-hallucinogenic, which could mean simpler treatment without hospitalization. Separately, lab data showed Clearmind's nasal MEAI formula sticks to tissue better, a small but useful development step.

    These two updates build confidence in the drug's differentiation and delivery before the formal safety result.

  • Clearmind pivots into EV wireless charging with 51% acquisition Clearmind signed a definitive deal to buy 51% of Charging Robotics, an EV wireless charging firm, for $2.5 million plus a $1.5 million loan, closing around September 7. It is a surprising move away from its psychedelic-medicine focus and could distract or dilute, though it may add a new revenue path.

    This is a major strategic shift that changes what Clearmind is as a company and raises real questions for investors.

  • Big pharma money flowing into psychedelics lifts the whole sector Eli Lilly agreed to pay up to $3.8 billion for AtaiBeckley, a major vote of confidence in psychedelic medicine. Large cannabis deals also made headlines. A rising tide of sector interest can pull small stocks like Clearmind higher, though it does not change Clearmind's own results.

    Sector-wide deal activity is a real force behind small psychedelic stocks, even if it is not company-specific.

Latest
▲3

Clearmind's alcohol drug trial hits safety goal, but EV charging pivot raises questions

  • CMND-100 clears key safety hurdle in alcohol use disorder trial Clearmind's lead drug CMND-100 met its main safety goal in Part A of a Phase 1/2 trial: all 24 healthy volunteers finished dosing, with no serious side effects across four dose levels. This is the biggest de-risking event so far and supports moving into patients with alcohol use disorder.

    This is the single most important new event for CMND's core drug program and directly drives the stock's value.

  • Early trial buzz and better nasal formulation support the drug story Doctors at Yale and Johns Hopkins gave a positive early read on CMND-100, noting it is non-hallucinogenic, which could mean simpler treatment without hospitalization. Separately, lab data showed Clearmind's nasal MEAI formula sticks to tissue better, a small but useful development step.

    These two updates build confidence in the drug's differentiation and delivery before the formal safety result.

  • Clearmind pivots into EV wireless charging with 51% acquisition Clearmind signed a definitive deal to buy 51% of Charging Robotics, an EV wireless charging firm, for $2.5 million plus a $1.5 million loan, closing around September 7. It is a surprising move away from its psychedelic-medicine focus and could distract or dilute, though it may add a new revenue path.

    This is a major strategic shift that changes what Clearmind is as a company and raises real questions for investors.

  • Big pharma money flowing into psychedelics lifts the whole sector Eli Lilly agreed to pay up to $3.8 billion for AtaiBeckley, a major vote of confidence in psychedelic medicine. Large cannabis deals also made headlines. A rising tide of sector interest can pull small stocks like Clearmind higher, though it does not change Clearmind's own results.

    Sector-wide deal activity is a real force behind small psychedelic stocks, even if it is not company-specific.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 2026
▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

  • First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.

    The profit turnaround is the core fundamental change behind the stock's re-rating.

  • AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.

    A major global partnership is a new growth catalyst that directly lifts investor expectations.

  • New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.

    Regulatory progress on an existing product is a concrete new pipeline milestone.

  • Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.

    Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 2026
▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

  • First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.

    The profit turnaround is the core fundamental change behind the stock's re-rating.

  • AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.

    A major global partnership is a new growth catalyst that directly lifts investor expectations.

  • New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.

    Regulatory progress on an existing product is a concrete new pipeline milestone.

  • Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.

    Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest
▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

  • First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.

    The profit turnaround is the core fundamental change behind the stock's re-rating.

  • AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.

    A major global partnership is a new growth catalyst that directly lifts investor expectations.

  • New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.

    Regulatory progress on an existing product is a concrete new pipeline milestone.

  • Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.

    Institutional buying and supportive regulation are fresh demand and policy tailwinds.